SCHEMBL363406

SCHEMBL363406

CC(F)(F)c1ncc(O)cc1Cl

nearest known ligand 0.34

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 1/20 0.34
HSD17B10 Q99714 2/20 0.33
CYP3A4 P08684 1/20 0.33
HPGD P15428 1/20 0.33
CRHBP P24387 1/20 0.33
CRHR2 Q13324 1/20 0.33
PDK1 Q15118 1/20 0.33
PDK2 Q15119 1/20 0.33
PDK3 Q15120 1/20 0.33
PDK4 Q16654 1/20 0.33
MAPK1 P28482 1/20 0.33
ALDH1A1 P00352 3/20 0.32
IDH1 O75874 4/20 0.31
RXRA P19793 1/20 0.30
GRIN1 Q05586 1/20 0.30
GRIN2B Q13224 1/20 0.30
GAA P10253 1/20 0.30
PLAU P00749 1/20 0.30
PKM P14618 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL370663 0.84 HSD17B10 (0.36) HSD17B10CYP3A4HPGDCRHBPCRHR2
SCHEMBL363834 0.84 ALDH1A1 (0.37) RAB9AHSD17B10CYP3A4HPGDCRHBP
SCHEMBL364528 0.82 HSD17B10 (0.34) HSD17B10CYP3A4HPGDCRHBPCRHR2
SCHEMBL16175295 0.80 MAPK1 (0.33) HSD17B10CYP3A4HPGDCRHBPCRHR2
SCHEMBL29989503 0.77 PLAU (0.40) HSD17B10ALDH1A1IDH1PLAUPKM
SCHEMBL29268175 0.77 PLAU (0.40) HSD17B10ALDH1A1IDH1PLAUPKM
SCHEMBL14831219 0.77 RXRA (0.38) RAB9AALDH1A1RXRAGRIN1GRIN2B
SCHEMBL14831113 0.73 ALDH1A1 (0.37) ALDH1A1IDH1GAA
SCHEMBL29268113 0.72 SMN1; SMN2 (0.42) RXRA
SCHEMBL29989998 0.72 SMN1; SMN2 (0.42) RXRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2593432-B1 N-SULFONYLBENZAMIDE DERIVATIVES USEFUL AS VOLTAGE GATED SODIUM CHANNEL INHIBITORS PFIZER LTD (GB) 2014-10-22 EP disclosed
US-8592629-B2 Sulfonamide derivatives as Nav 1.7 inhibitors PFIZER LIMITED (GB) 2013-11-26 US disclosed
EP-2593432-A1 N-SULFONYLBENZAMIDE DERIVATIVES USEFUL AS VOLTAGE GATED SODIUM CHANNEL INHIBITORS Pfizer Limited (GB) 2013-05-22 EP disclosed
WO-2012007861-A1 N-SULFONYLBENZAMIDE DERIVATIVES USEFUL AS VOLTAGE GATED SODIUM CHANNEL INHIBITORS PFIZER LIMITED (GB) 2012-01-19 WO disclosed
US-20120010183-A1 Chemical Compounds PFIZER LIMITED (GB) 2012-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010183-A1 Chemical Compounds SCN1A, SCN1B, SCN7A RAB9A 1252/4885HSD17B10 1528/4885CYP3A4 471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.